Jennifer Irvine

Jennifer Irvine is a Lecturer in the Department of Pharmacology at Monash University. Her research focuses on cardiovascular pharmacology, particularly the role of nitroxyl (HNO) and angiotensin receptor agonists in regulating endothelial function, inflammation, and cardiomyocyte hypertrophy. She has contributed to studies on soluble guanylyl cyclase activation and its therapeutic implications in hypertension and cardiac remodeling.

Her academic work aligns with UN Sustainable Development Goals related to good health and well-being (SDG 3). She is a member of the Monash Partners advisory panel (2018–2021), contributing to healthcare policy and academic partnerships. Her research integrates molecular biology, drug development, and translational cardiovascular science.

Irvine’s publications explore anti-inflammatory effects of pharmacological agents, mechanisms of vascular dysfunction, and novel therapeutic targets for cardiovascular diseases. Her studies often involve in vitro and in vivo models to investigate cellular pathways involved in hypertension and heart failure.